Evidence map›Paper›PMID 42200221›Full record

ArticleMolecular pharmaceutics2026

Linker Optimization in Lu-177 Labeled αvβ6-Integrin Binding Peptide Trimers for Targeted Radionuclide Therapy of Cancer.

Nghia Trong Nguyen, Tim Rheinfrank, Stefan Stangl, Falco Reissig, Susanne Kossatz, Johannes Notni

Abstract read
In one paragraph

Article in Molecular pharmaceutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Nghia Trong NguyenDepartment of Nuclear Medicine, TUM University Hospital and Central Institute for Translational Cancer Research, (TranslaTUM), School of Medicine, Technical University Munich, Munich 81675, Germany.
Tim RheinfrankDepartment of Nuclear Medicine, TUM University Hospital and Central Institute for Translational Cancer Research, (TranslaTUM), School of Medicine, Technical University Munich, Munich 81675, Germany.
Stefan StanglDepartment of Nuclear Medicine, TUM University Hospital and Central Institute for Translational Cancer Research, (TranslaTUM), School of Medicine, Technical University Munich, Munich 81675, Germany.
Falco ReissigTRIMT GmbH, Carl-Eschebach-Str. 7, Radeberg 01454, Germany.
Susanne KossatzDepartment of Nuclear Medicine, TUM University Hospital and Central Institute for Translational Cancer Research, (TranslaTUM), School of Medicine, Technical University Munich, Munich 81675, Germany.
Johannes NotniTRIMT GmbH, Carl-Eschebach-Str. 7, Radeberg 01454, Germany.ORCID 0000-0002-3964-3391

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Theranostic radiopharmaceuticals exploit the same molecular target for diagnosis and therapy. Among emerging pan-cancer targets, αvβ6-integrin is highly expressed on various malignant cell types and can be imaged clinically with Ga-68-Trivehexin. However, therapeutic αvβ6-integrin-directed radioligands remain scarce. Here, Lu-177-labeled multimerics of the cyclic nonapeptides Tyr2, sequence c(YRGDLAYp(

Indexed as

Antigens, NeoplasmIntegrinsLutetiumNeoplasmsPeptidesRadioisotopesRadiopharmaceuticalsAnimalsCell Line, TumorFemaleHumansMiceMice, NudeTissue DistributionXenograft Model Antitumor AssaysAntigens, Neoplasmintegrin alphavbeta6IntegrinsLutetiumLutetium-177PeptidesRadioisotopesRadiopharmaceuticalsbioconjugatespeptidesradiopharmaceuticalstheranosticsαvβ6-integrin

Identifiers

PMID42200221
PMCPMC13343512

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.